Patents by Inventor Frédéric Jaisser

Frédéric Jaisser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF NGAL PROTEIN
    Publication number: 20220054493
    Abstract: This invention relates to compounds that are inhibitors of NGAL activity, and applications thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: February 24, 2022
    Inventors: Frédéric JAISSER, Ernesto MARTINEZ-MARTINEZ, Paul MULDER, Antoine OUVRARD-PASCAUD, Philippe BERNARD, Quoc Tuan DO
  • Method for treatment of heart failure
    Patent number: 10059946
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 28, 2018
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Frédéric Jaisser, Nicolette Farman
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE
    Publication number: 20170002358
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Institut National de la Sante et de la Recherche M edicale (INSERM)
    Inventors: Frédéric JAISSER, Nicolette FARMAN
  • Methods for the treatment of heart failure
    Patent number: 9533041
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: January 3, 2017
    Assignee: Institut National de la Santé et de la Recherche Médicale
    Inventor: Frédéric Jaisser
  • Methods and compositions for stimulating reepithelialisation during wound healing
    Patent number: 9241944
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialization during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialization of the skin or of the cornea during wound healing.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 26, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique Hopitaux de Paris, Universite Paris Descartes
    Inventors: Nicolette Farman, Francine Behar-Cohen, Frédéric Jaisser
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE
    Publication number: 20130315932
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Application
    Filed: December 5, 2011
    Publication date: November 28, 2013
    Inventor: Frédéric Jaisser
  • METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING
    Publication number: 20130143850
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.
    Type: Application
    Filed: June 16, 2011
    Publication date: June 6, 2013
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Nicolette Farman, Francine Behar-Cohen, Frédéric Jaisser
  • Regulatory sequences of the mouse villin gene—use in transgenesis
    Patent number: 7067648
    Abstract: The invention relates to regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of the intestine and uro-genital tracts. The invention also relates to recombinant constructs comprising said regulatory sequences, for the control of the targeted expression of determined nucleic acid sequences so-called (heterologous sequences or also transgenes), in cells or tissues originating from the intestinal mucosa. A further object of the invention is to provide cells, tissues or organisms including animals, expressing said determined nucleic acid sequences in a targeted manner.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: June 27, 2006
    Assignees: Institut Curie, Centre National de la Recherche and Scientifique
    Inventors: Daniel Pinto, Sylvie Robine, Frédéric Jaisser, Daniel Louvard